Topics

Moffitt research of Selinexor for multiple myeloma facilitates FDA approval

20:00 EDT 23 Jul 2019 | AAAS

(H. Lee Moffitt Cancer Center & Research Institute) A first-in-class drug recently granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with heavily pretreated multiple myeloma has been the subject of study at Moffitt Cancer Center for years. Now, selinexor (XPOVIO™, Karyopharm Therapeutics) used in combination with the corticosteroid dexamethasone will offer another option for patients with multiple myeloma who have exhausted the most common therapies for the disease.

Original Article: Moffitt research of Selinexor for multiple myeloma facilitates FDA approval

NEXT ARTICLE

More From BioPortfolio on "Moffitt research of Selinexor for multiple myeloma facilitates FDA approval"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...